Analysts See $-0.22 EPS for Cellect Biotechnology Ltd (APOP); Ra Capital Management Upped Achillion Pharmaceuticals (ACHN) Position

August 28, 2017 - By Michael Collier

Analysts expect Cellect Biotechnology Ltd (TLV:APOP) to report $-0.22 EPS on September, 7.They anticipate $0.21 EPS change or 2,100.00% from last quarter’s $-0.01 EPS. After having $-0.04 EPS previously, Cellect Biotechnology Ltd’s analysts see 450.00% EPS growth. About 38 shares traded. Cellect Biotechnology Ltd (TLV:APOP) has 0.00% since August 28, 2016 and is . It has underperformed by 16.70% the S&P500.

Ra Capital Management Llc increased Achillion Pharmaceuticals Inc (ACHN) stake by 13.3% reported in 2016Q4 SEC filing. Ra Capital Management Llc acquired 1.60M shares as Achillion Pharmaceuticals Inc (ACHN)’s stock 0.00%. The Ra Capital Management Llc holds 13.63 million shares with $56.31M value, up from 12.03 million last quarter. Achillion Pharmaceuticals Inc now has $672.87M valuation. The stock decreased 0.81% or $0.04 on August 25, reaching $4.92. About shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 47.61% since August 28, 2016 and is downtrending. It has underperformed by 64.31% the S&P500.

Ra Capital Management Llc decreased Zogenix Inc stake by 204,929 shares to 2.45M valued at $29.78 million in 2016Q4. It also reduced Aimmune Therapeutics Inc stake by 615,277 shares and now owns 677,663 shares. Tg Therapeutics Inc (NASDAQ:TGTX) was reduced too.

Among 10 analysts covering Achillion Pharma (NASDAQ:ACHN), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Achillion Pharma had 21 analyst reports since August 13, 2015 according to SRatingsIntel. On Friday, September 23 the stock rating was maintained by Chardan Capital Markets with “Sell”. Wedbush initiated the shares of ACHN in report on Friday, September 23 with “Outperform” rating. As per Thursday, July 7, the company rating was upgraded by JMP Securities. The firm earned “Market Perform” rating on Friday, January 29 by Leerink Swann. The company was upgraded on Tuesday, September 8 by UBS. The company was upgraded on Friday, November 4 by Chardan Capital Markets. The rating was maintained by Maxim Group with “Buy” on Thursday, February 25. The rating was maintained by Leerink Swann on Friday, August 11 with “Buy”. The rating was maintained by Maxim Group with “Buy” on Thursday, August 13. As per Friday, February 26, the company rating was upgraded by Robert W. Baird.